Yesterday (9 May 65), Dr. Supakit Sirilak, Director-General of the Department of Medical Sciences and Dr. Throne Upaphong, Deputy Director-General of the Department of Medical Sciences Press release on surveillance for Covid-19 strains in Thailand by Dr. Supakit said that currently, Covid-19 in Thailand is a 100% omikron strain from 747 surveillance during April 30 – May 6, 2022. Found all omikrons. No other species were found. The WHO is monitoring three subspecies of omikron, BA.4 and BA.5, which are found mainly in South Africa and some European countries. and BA.2.12.1, mostly found in the United States. Because it was noted that it may be the reason why more patients are hospitalized. or may be more severe
Tag:
nature
New..a smart watch with special specifications for lovers of wanderlust and adventures in nature
written by Alexandra Hartman Editor-in-Chief
Country: Amazfit has announced its new smartwatch, which is designed to be among the most suitable for lovers of wanderers and adventures in nature.
The new Amazfit T-Rex Pro 2 watch comes with a very durable body made of reinforced plastic and metal, designed to withstand shocks according to MIL-STD-810G military standards, and is water and dust resistant according to 10 ATM standard.
The watch has a 1.39-inch AMOLED screen with a display resolution of (454/454) pixels, its brightness is approximately 1000 cd / m, and it is protected by a layer of anti-shock and scratch-resistant glass.
This watch is equipped with comfortable rubber straps in distinctive colors of Black, Desert Khaki, and Wild Green, Bluetooth 5.0 systems for wireless pairing with phones and smart devices, GPS positioning systems, an electronic compass, a sensor to measure the surrounding light, advanced sensors to measure heart rates, and monitoring systems. physical activity of the user.
Amazfit equipped it with a battery with a capacity of 500 mAh, which is enough to work 24 days on a single charge in the case of normal use and 10 days in the case of intensive use.
Expectations that trade between Turkey and Saudi Arabia will return to normal at an accelerating pace
written by Alexandra Hartman Editor-in-Chief
Al-Marsad newspaper – dpa: The Council of Saudi Chambers of Commerce expects the kingdom’s imports from Turkey to rise in the near future, in the latest sign of improving relations between two of the largest Islamic countries.
Today, Wednesday, the Turkish News Agency quoted sources in the Council of Chambers of Commerce that the import of Turkish goods by merchants will return to normal at an accelerated pace, as soon as the official announcement of the return of relations to normal.
The Kingdom’s imports from Turkey rose by 2.8% in the first two months of 2022, according to data from the Saudi General Authority for Statistics.
The value of imports in January and February reached 71.3 million riyals ($19 million), compared to 69.4 million riyals ($18.5 million) in the corresponding period of 2021. This comes following the Kingdom’s imports from Turkey declined in 2021 by 62.3%, to 3.32 billion riyals ($886 million) compared to 8.82 billion riyals ($2.35 billion) in 2020.
This probiotic improves immunotherapy to treat kidney cancer
written by Alexandra Hartman Editor-in-Chief
Updated:
Keep
The use of a probiotic improves the treatment of liver cancer. The data of a work that is published today in «
Nature Medicine» shows that this live biotherapeutic, CBM588, added to an immunotherapy drug, nivolumab/ipilimumabsignificantly improved progression-free survival in patients with metastatic kidney cancer compared to the use of nivolumab/ipilimumab alone.
“To our knowledge, this is the first randomized clinical trial to show that a live bacterial product can modulate the gastrointestinal microbiome and improve response to immunotherapy in cancer patients,” said Sumanta K. Pal, Department of Medical Oncology and Research. therapeutic in
City of Hope (USA) and lead author of the study
For the researcher,
“These results may help improve treatment options for kidney cancer patients and is an important foundational step in generating more effective targeted therapies for cancer treatment.”
CBM588 is a non-pathogenic bacterium that has multiple documented beneficial effects on the human microbiome. It produces short-chain fatty acids (mainly butyric acid), a well-known source of energy for the lining of the gastrointestinal tract, and has immunomodulatory properties. The bacterial strain appears to exert additional beneficial effects, including inhibition of pathogenic microorganisms and helping to restore the gastrointestinal lining and decrease intestinal imbalance.
Last summer, this center granted an exclusive worldwide license to
Osel Inc.a company that develops live biotherapeutics for the modulation of the human microbiome, for the intellectual property on the novel use of CBM588 to improve the efficacy of checkpoint inhibitors to treat cancer.
In this phase I clinical trial, 30 treatment-naïve patients with metastatic kidney cancer (renal cell carcinoma) were randomized to receive oral CBM588 in combination with nivolumab/ipilimumab or nivolumab/ipilimumab alone.
The now published data now show a significant improvement in progression-free survival in patients treated with CBM588 plus nivolumab/ipilimumab (12.7 months) compared to nivolumab/ipilimumab alone (2.5 months).
In addition, the use of CBM588 in combination therapy was associated with an increased response rate compared to the use of nivolumab/ipilimumab therapy alone (58% vs. 20%).
Although there was no significant difference between the treatment groups in the amount of bacteria of the genus Bifidobacterium, patients who responded to CBM588 with nivolumab/ipilimumab treatment had significant increases in Bifidobacterium species. There was no significant difference in reported treatment-related toxicity between the two groups.
“Over the last few years, the field of immunotherapy has been closely studying how the gastrointestinal microbiome can enhance the effectiveness of the immune checkpoint for cancer treatment,” says Thomas Parks, director of product development at Osel.
The authors conclude that their data appear to support the potential of CBM588 to improve outcomes for cancer patients undergoing immunotherapy. However, the results will need to be confirmed in larger studies and for additional tumor types.